Loading
A phase 1/2 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, terminated.
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant is a phase 1/2 interventional study registered as NCT02065869 by Bellicum Pharmaceuticals, with 187 participants enrolled, started 2014-04. Conditions recorded: Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndrome, Primary Immunodeficiency, Anemia, Aplastic, Osteopetrosis, Hemoglobinopathies, Cytopenia, Fanconi Anemia, Diamond Blackfan Anemia, Thalassemia and Anemia, Sickle Cell. Interventions recorded: BPX-501 T cells and Rimiducid.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/